Is extended pelvic lymph node dissection for prostate cancer the only recommended option? A systematic over-view of the literature

Thomas Rees¹, Nicholas Raison², Mohammed Iqbal Sheikh³, Zahra Jaffry⁵, Sanjeev Madaan⁴, Ben Challacombe⁵, Kamran Ahmed¹, Prokar Dasgupta¹

ABSTRACT

Objective: Pelvic lymph node dissection (PLND) is performed alongside radical prostatectomy as the most accurate method of staging prostate cancer. Yet the potential therapeutic benefits of lymphadenectomy are yet to be confirmed.

Material and methods: A PubMed database search was performed to identify all papers comparing techniques for PLND or none. The primary outcome measure was long term oncological outcomes. Studies looking at men with clinically localized prostate cancer at the time of radical prostatectomy who received no adjuvant treatment were included. Previous reviews and single case reports were excluded. The subsequent available papers were then systematically reviewed.

Results: Limited PLND provides no benefit in low risk prostate cancer and is unlikely to provide a therapeutic benefit in higher risk groups either when compared with no PLND. Extended PLND may provide some therapeutic benefit, particularly in patients with occult metastases; however, the evidence base for this is not particularly strong and may be down to statistical phenomena.

Conclusion: When performed in prostate cancer patients, PLND should be extended, as it is a more accurate staging tool and may provide therapeutic benefit to some patients. However, to properly assess this, randomised controlled studies need to be performed in this area.

Keywords: Pelvic lymph node dissection; prostatectomy; prostate cancer; systematic review; outcomes.

Introduction

In the management of prostate cancer (PCa), the role of pelvic lymph node dissection (PLND) at the time of radical prostatectomy has long been debated. Whilst it is reasonably well established as the best method for accurate staging of PCa,¹ its role in treatment and whether it has any therapeutic benefit is still widely contested.² It has been proposed that lymphadenectomy may remove undetectable micrometastases and therefore potentially improve survival.³ Yet the extent of PLND varies greatly between surgeons and centres, with some performing a limited PLND (IPLND), confined to the external iliac and obturator fossa areas, and others choosing an extended PLND (ePLND). Even then debate consider variability exists in the definition of ePLND with some surgeons removing the external iliac, hypogastric and obturator nodes and other including the pre sacral and pre sciatic nodes.⁴ Risk of lymph node metastasis in PCa largely depends on the patient’s risk group patients at the time of diagnosis.⁵ In lower risk patients it is often felt that the risks of performing PLND outweigh any potential cases. Furthermore in comparison to other malignancy such as breast, a greater variation in the routes of lymphatic spread of cancer is found.⁶ The goal of this review is to assess any available papers that look at comparing the effects of PLND on the outcomes of PCa treatment.

Material and methods

A series of PubMed searches were carried out between November and December 2015 using...
combinations of the following terms; pelvic lymph node dissection, lymphadenectomy, prostatectomy, prostate cancer, outcome, survival, and treatment. Filters were applied to exclude any studies not done in humans. The reference lists from any selected papers were also searched for relevant papers that may have been missed by the initial searches.

Papers for inclusion would look at men with clinically localized primary PCa at the time of radical prostatectomy. The papers would need to show a direct comparison between ePLND and lPLND, or between either of these and no dissection at all. IPLND was defined as removal of the external iliac and obturator nodes, and ePLND as the removal of these plus either the hypogastric, pre-sciatic or pre-sacral nodes or any combination thereof. Patients would need to have not received any adjuvant therapy during the period of the study. Randomised controlled trials and prospective or retrospective analyses looking at men with PCa from all risk groups as stratified by D’Amico[5] would be included. All previous reviews were automatically excluded, as were single case reports, editorial pieces and titles that were not available in English or simply not available.

The outcome measures of interest were: biochemical recurrence (BCR), defined as a prostate specific antigen reading of 0.2 or greater following radical prostatectomy, cancer specific survival (CSS). These were chosen as CSS would be the most definite way of assessing the outcome of therapy, but given the long follow up time required BCR could be used as an indicator of disease progression. The search technique is summarised in Figure 1.

**Results**

In total, sixteen studies were identified that compared PLND in terms of outcome. Twelve articles made a direct comparison between defined extents of PLND. Of these, seven[7-13] compared IPLND with no dissection at all and the remaining five[14-18] compared ePLND and IPLND, with one study[18] also including no PLND. In some of the studies, the term standard PLND was used but in these cases the extent matched that of IPLND and so will be referred to as IPLND here. Of the twelve, five were exclusively looking at patients in the low risk group, two looked at those at intermediate and high risk, one in exclusively high risk patients and one across all risk groups.

The remaining four[19-22] studies from the total of sixteen used the number of lymph nodes removed as a surrogate for the extent of dissection and were deemed to have a suitable format for inclusion in the review.

---

**Figure 1. PRISMA flow diagram**

It is worth noting that there was one paper[23] that was included after the literature search but it had actually been retracted due to misconduct by one of the authors and was no longer available. A significant degree of clinical and methodological heterogeneity was seen across all studies which prevented pooled analysis of the results. Throughout the studies, there was a great degree of variance in the methodology used, including patient groups, length of follow up and outcome measures, which made direct comparison between the papers (with the exception of the updates) very challenging. Comparable data taken from the direct comparison studies are presented in Table 1.

**IPLND vs. no PLND**

Of the 7 studies studies that compared IPLND with no PLND in exclusively low risk patients, PLND showed no benefit in terms of BCR. Fergany et al.[7], Bhatta-Dhar et al.[8] and Weight et al.[9] were a series of papers following the same group of patients over 4, 6 and 10 years respectively. At no stage did they find any significant difference in BCR free survival rates (BCRFS) at 5 years (74% vs. 70%, p=0.11). Ku et al.[11] looked at 222 Japanese men with low risk PCa and found the 5 year BCRFS rates to be nearly identical between the two groups (p=0.65).

When comparing IPLND with none in 4693 patients across all risk groups, Berglund et al.[10] also found no significant difference in BCRFS at 5 years (74% vs. 70%, p=0.11). Ku et al.[11]...
looked at lPLND compared with no PLND in 199 Korean men with high risk PCa and found no significant difference in BCRFS rates (p=0.355).

### Table 1. Summary data of all comparative studies

<table>
<thead>
<tr>
<th>Paper</th>
<th>Year</th>
<th>Comparison</th>
<th>Total Pts</th>
<th>ePLND/ equivalent</th>
<th>lPLND/ equivalent</th>
<th>No PLND</th>
<th>Risk Groups</th>
<th>FU</th>
<th>BCRFS ePLND</th>
<th>BCRFS lPLND</th>
<th>BCRFS No PLND</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bivalacqua et al.[17]</td>
<td>2013</td>
<td>ePLND vs. lPLND</td>
<td>4265</td>
<td>2279</td>
<td>1986</td>
<td>-</td>
<td>All</td>
<td>126</td>
<td>30.1% @5 yrs</td>
<td>7.1% @5 yrs</td>
<td>0.018*</td>
<td></td>
</tr>
<tr>
<td>Kim et al.[16]</td>
<td>2013</td>
<td>ePLND vs. lPLND</td>
<td>464</td>
<td>170</td>
<td>294</td>
<td>-</td>
<td>Int. &amp; High</td>
<td>36</td>
<td>77.8% @3 yrs</td>
<td>73.5% @3 yrs</td>
<td>0.497</td>
<td></td>
</tr>
<tr>
<td>Allaf et al.[15]</td>
<td>2004</td>
<td>ePLND vs. lPLND</td>
<td>4000</td>
<td>2135</td>
<td>1865</td>
<td>-</td>
<td>All</td>
<td>38</td>
<td>91% @4 yrs</td>
<td>97% @4 yrs</td>
<td>0.16</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>575</td>
<td>-</td>
<td>372</td>
<td>203</td>
<td>Low</td>
<td>38</td>
<td>16.5% @5 yrs</td>
<td>86% @6 yrs</td>
<td>0.28</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>7036</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>All</td>
<td>69.6</td>
<td>86% @6 yrs</td>
<td>88% @6 yrs</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4693</td>
<td>-</td>
<td>3961</td>
<td>732</td>
<td>All</td>
<td>62.5</td>
<td>74% @5 yrs</td>
<td>70% @5 yrs</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>470</td>
<td>211</td>
<td>259</td>
<td>-</td>
<td>Int. &amp; High</td>
<td>58.5%</td>
<td>46.4% @10 yrs</td>
<td>87.6% @5 yrs</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>614</td>
<td>319</td>
<td>295</td>
<td>-</td>
<td>All</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>&lt;0.001*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>492</td>
<td>54</td>
<td>231</td>
<td>207</td>
<td>All</td>
<td>37.0</td>
<td>14.7% @1.1 yrs</td>
<td>3.4% @0.9 yrs</td>
<td>&lt;0.001*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>139</td>
<td>-</td>
<td>85</td>
<td>54</td>
<td>Low</td>
<td>69.4</td>
<td>88.3% @7 yrs</td>
<td>82.4% @7 yrs</td>
<td>0.278</td>
<td></td>
</tr>
<tr>
<td>Ku et al.[11]</td>
<td>2011</td>
<td>IPLND vs. no PLND</td>
<td>199</td>
<td>-</td>
<td>111</td>
<td>88</td>
<td>High</td>
<td>36</td>
<td>87.6% @3 yrs</td>
<td>87.1% @3 yrs</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td>Schiavina et al.[22]</td>
<td>2010</td>
<td>&gt;9 nodes vs. 5-9 nodes</td>
<td>470</td>
<td>211</td>
<td>259</td>
<td>-</td>
<td>Int. &amp; High</td>
<td>58.5%</td>
<td>46.4% @10 yrs</td>
<td>87.6% @5 yrs</td>
<td>0.023*</td>
<td></td>
</tr>
<tr>
<td>Schiavina et al.[21]</td>
<td>2007</td>
<td>&gt;9 nodes vs. 1-9 nodes</td>
<td>614</td>
<td>319</td>
<td>295</td>
<td>-</td>
<td>All</td>
<td>62.5</td>
<td>74% @5 yrs</td>
<td>70% @5 yrs</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>Weight et al.[9]</td>
<td>2007</td>
<td>IPLND vs. no PLND</td>
<td>4693</td>
<td>-</td>
<td>3961</td>
<td>732</td>
<td>All</td>
<td>-</td>
<td>88% @10 yrs</td>
<td>88% @10 yrs</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Joslyn and Konety[19]</td>
<td>2006</td>
<td>Lymph nodes removed vs. none</td>
<td>9182</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>All</td>
<td>+120</td>
<td>Not reported</td>
<td>Not reported</td>
<td>&lt;0.001*</td>
<td></td>
</tr>
<tr>
<td>DiMarco et al.[10]</td>
<td>2005</td>
<td>&lt;5 nodes vs. 5-9 vs. 10-14 vs. 15-19 vs. &gt;19</td>
<td>7036</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>All</td>
<td>69.6</td>
<td>86% @6 yrs</td>
<td>88% @6 yrs</td>
<td>0.28</td>
<td></td>
</tr>
<tr>
<td>Bhatta-Dhar et al.[6]</td>
<td>2004</td>
<td>IPLND vs. no PLND</td>
<td>336</td>
<td>-</td>
<td>140</td>
<td>196</td>
<td>Low</td>
<td>-</td>
<td>34.4% @5 yrs</td>
<td>16.5% @5 yrs</td>
<td>0.07</td>
<td></td>
</tr>
</tbody>
</table>

Key: Pts: patients, FU: Average (median/mean) Follow up, BCRFS: Biochemical recurrence free survival Int: Intermediate Risk Group

### IPLND vs. ePLND
When comparing ePLND with IPLND, Allaf et al.[15] looked at 5 year BCRFS in 4000 patients across all risk groups. They failed
to find any significant difference between the two techniques though they reported a trend towards increased survival in those who received ePLND (34.4% vs. 16.5%, p=0.07). Further analysis showed that there was a significant difference in BCRFS at 5 years (42.9% vs. 10.0%, p=0.01) in a subgroup of men found to have positive lymph nodes in less than 15% of the nodes removed. In a later paper, Bivalacqua et al.\[17\] reported these results with a follow up of 10.5 years. They showed a significant finding for 5-year BCRFS rates at 30.1% vs. 7.1% (p=0.018) and a trend towards improved CSS at 10 years for the ePLND group (83.6% vs. 52.6%, p=0.199). In subsequent analysis with Cox proportional hazard models, the proposed benefit to BCRFS lost its significance though they still reported a trend, (hazard ratio (HR): 0.596; 95% confidence interval (CI) 0.313-1.034; p=0.064) and there was no difference seen for CSS (HR: 0.495; CI 0.163-1.504; p=0.215). Again, in the subset of patients with node positive disease and less than 15% involvement in sampled nodes, they reported significant differences in BCRFS at 5 years, with the ePLND subgroup rate at 39.4% and the IPLND rate at 0.0% (p=0.003). This gave a HR of 0.350 (CI: 0.150-0.819; p=0.016).

Liss et al.\[18\] looked at ePLND compared with IPLND during robot assisted radical prostatectomy and also compared this to those who received no PLND. With 492 patients across all risk groups they found that ePLND was significantly associated with an increased risk of BCR (p=0.001, depicted in a Kaplan-Meier graph). However after multivariate analysis adjusting for the fact that high-risk patients were more likely to receive an ePLND this association disappeared (p=0.294).

Kim et al.\[16\] looked at ePLND versus IPLND in 464 intermediate and high-risk patients that received robot assisted surgery. They propensity score matched the groups to try and eliminate some of the bias associated with retrospective analysis. They found that in the whole cohort the 3 year BCRFS in the ePLND group was lower than the IPLND group (72.7% vs. 79.8%, HR: 1.48, CI 1.00-2.18, p=0.048), however, in the matched cohort they reported that this reversed and suggested a trend towards favouring ePLND (77.8% vs. 73.5%, HR: 0.85, CI0.52-1.36, p=0.497) although this wasn’t statistically significant.

When exclusively looking at 200 patients from the high-risk group, Jung et al.\[14\] showed greater rates of diagnosis of lymph node metastasis with ePLND but failed to show improved BCRFS compared to IPLND. The study was limited by the median follow up was just 24 months (interquartile range (IQR): 15-34) and 13 months (IQR: 10-17) respectively.

In the papers that used the number of nodes removed as a surrogate for the extent of dissection, Joslyn and Koney\[19\] identified 9,182 patients in the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program who had undergone radical prostatectomy with a recorded number of lymph nodes removed and a minimum 10 years follow up. They found that CSS was improved in all patients that received PLND and had more than 4 nodes removed compared to 3 or less (HR: 0.77, CI 0.64-0.93, p=0.0069), and that CSS in patients found to have negative nodes after PLND improved if 10 or greater nodes were removed (HR: 0.85 CI, 0.72-0.99, p=0.03282).

Similarly, Schiavina et al.\[21\] found that in node negative patients, those with 10 or greater nodes removed had improved BCRFS than those with less taken (HR 0.564, CI 0.390-0.814, p=0.002). Another paper from the same author and institution\[22\] looking at intermediate and high-risk groups found that 10 or greater nodes removed was associated with a benefit to BCRFS rates at 10 years here too (58.5% vs. 46.4%, p=0.023). They also reported significance when looking at 33 patients found to have less than 2 positive nodes, with 10-year BCRFS rates of 43.3% for those with greater than 10 nodes removed compared to 0.0% for those with 1-9 nodes removed (p=0.014). Conversely, DiMarco et al.\[20\] found that when looking at 7036 patients with negative lymph nodes over a median follow up of 69 months, there was no association between increased lymph node dissection and improved BCRFS across all risk groups (Risk ratio: 0.99, CI 0.98-1.02, p=0.062).

**Discussion**

With PCa being the highest incidence cancer in men it is vital that treatment is effective. It is important to assess if PLND is part of the therapy, and not just in the staging the disease. Bader et al.\[3\] found PCA patients treated with surgery alone had disease free rates at ten years that compared favourably with those who received adjuvant treatment. They theorised that PLND may remove occult metastases from patients and prevent progression or recurrence. The aim of this review has been to assess the available data that directly compares the extents of PLND performed.

From the papers reviewed here, Fergany et al.\[71\], Bhatia-Dhar et al.\[9\], Weight et al.\[9\], Daimon et al.\[12\] and Mitsuzuka et al.\[13\] all conclude that there is no need to perform IPLND in low risk PCA patients. There are a number of issues with all these papers beyond the selection bias that comes with their retrospective approach. All were performed in single centres and have fairly low number of patients included. Despite this, their results were consistent and there are no studies that disagree with their findings. Similarly, Berglund et al.\[10\] and Ku et al.\[11\] found no benefit to
IPLND across other risk groups so it would seem sound to conclude that there is no need to perform IPLND in any patient with PCa. This is supported further by other studies that show the use of just IPLND removes significantly less lymph nodes than ePLND and is not as accurate a staging tool. Concerns that ePLND may cause more complications appear to be unfounded as recent studies show a similar incidence of complications between the two extents. Whether ePLND can be of benefit to low risk PCa patients cannot be assessed as no studies have looked into this area, however, current European guidance states that if PLND is to be performed at all it should be extended but there is no need to perform PLND in men from the low risk group as they are at very low risk of metastasis and potential complications outweigh any benefits.

In the case of ePLND, evidence is inconclusive. Jung et al. stated that there was no extra benefit in performing an extended dissection, however, the follow up time used was too short and while a supporting paper by DiMarco et al. had an appropriate length of follow up time at 5.8 years and a suitable study size, its use of number of nodes as a surrogate for the extent of PLND and variability in the PLNDs performed by the 5 surgeons make firm conclusions difficult to draw. Its findings are also at odds with the other papers using similar methods. Joslyn and Konyet looking at CSS. Whilst BCR is a helpful endpoint and can be used clinically to find PCa recurrence well before metastatic disease, many men who have BCR may not experience any symptoms associated with a recurrence of PCa and likewise many will not die from it. How clinically relevant BCR therefore is in terms of measuring the therapeutic benefit of PLND is questionable. The far more meaningful endpoint would be CSS, but as the course of PCa can be in excess of 15 years this was well beyond the design of the studies featured here and any future study would require a lot of long term planning.

It is worth noting that a review in 2005 on the role PLND in PCa acknowledged the potential therapeutic benefit but stated that randomised controlled studies would be required to properly assess this, and yet a decade later none have been done. To date, the only randomised study in the area was performed by Clark et al. in 2003 where they performed both ePLND and IPLND in the same patients, but did not look at BCR rates. With this lack of robust studies, it is interesting to note that two trials are listed on ClinicalTrials.gov that will randomise patients to either ePLND or IPLND and the results from these will be awaited with interest.

In conclusion, from this limited data set, it is possible to conclude that IPLND is of no therapeutic benefit during radical prostatectomy for prostate cancer. An ePLND may have a therapeutic benefit in terms of BCR, particularly in a subset of patients with minimal nodal disease, and in keeping with current guidelines when PLND is performed in intermediate and high risk patients it should be extended. However, the evidence for any potential benefit is not strong and may be down to stage migration from more accurate staging of the cancer and whether any benefit in BCR reduction translates into increased cancer specific survival remains to be seen. Randomised controlled studies are needed to establish answers to these questions but as these are awaited, ePLND can continue to be used in intermediate and high-risk patients as the most accurate staging method for prostate cancer.
References

1. Burkhard FC, Studer UE. The role of lymphadenectomy in high risk prostate cancer. World J Urol 2008;26:231-6. [CrossRef]


7. Fergany A, Kupelian PA, Levin HS, Zippe CD, Reddy C, Klein EA. No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients. Urology 2000;56:92-5. [CrossRef]


10. Berglund RK, Sadetsky N, DuChane J, Carroll PR, Klein EA. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: Results from CaPSURE. J Urol 2007;177:526-30. [CrossRef]


28. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. [CrossRef]

